Home Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
Article
Licensed
Unlicensed Requires Authentication

Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients

  • Noppawan Phumala Morales , Chalermkhwan Cherlermchoung , Suthat Fucharoen and Udom Chantharaksri
Published/Copyright: July 8, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 7

Abstract

Background: Iron-induced oxidative stress may be implicated in the alteration of the lipoprotein-associated antioxidant enzymes paraoxonase 1 (PON1) and platelet-activating factor acetylhydrolase (PAF-AH), leading to atherosclerosis-related vascular complication in patients with β-thalassemia hemoglobin E (β-thal/Hb E).

Methods: Plasma and lipoprotein enzyme activities of PON1 and PAF-AH were studied in 13 mild to moderate and 15 severe cases of β-thal/Hb E in comparison with 15 normal subjects.

Results: PON1 activity was significantly reduced in association with oxidative stress in the patients. There were significant correlations between high-density lipoprotein (HDL)-PON1 activity and oxidative stress markers, including plasma levels of α-tocopherol (r=0.694 p<0.001) and the ratio of cholesteryl linoleate to cholesteryl oleate (CL/CO, r=0.662, p<0.001) in HDL. On the other hand, PAF-AH activity was markedly increased in patients by approximately two-fold and three- to four-fold in plasma and lipoproteins, respectively. Significant correlations of low-density lipoprotein (LDL) and HDL-PAF-AH activity with plasma iron, α-tocopherol and the CL/CO ratio were also demonstrated.

Conclusions: We suggest that impairment of PON1 activity may be directly caused by oxidative damage, while increased PAF-AH activity possibly results from oxidative stress-induced inflammatory response in β-thal/Hb E patients.

Clin Chem Lab Med 2007;45:884–9.


Corresponding author: Noppawan Phumala Morales, Department of Pharmacology, Faculty of Science, Mahidol University, Rama 6 Rd., Rajatevee, Bangkok 10400, Thailand Phone: +66-2-2015508, Fax: +66-2-3547157

Received: 2006-12-13
Accepted: 2007-2-25
Published Online: 2007-07-08
Published in Print: 2007-07-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Pharmacogenomics and Personalized Medicine – a global reality check
  2. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
  3. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
  4. Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
  5. Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
  6. Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs
  7. A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment
  8. Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
  9. On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test
  10. High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes
  11. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
  12. A novel application of melting curves: utility of peak area calculation for relative methylation quantification
  13. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians
  14. Tumor necrosis factor-α and oxidant status are essential participating factors in unexplained recurrent spontaneous abortions
  15. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
  16. Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients
  17. Direct determination of selenium in human serum by inductively coupled plasma-collision cell-mass spectrometry
  18. Within-subject variation of plasma resistin levels over a 1-year period
  19. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects
  20. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
  21. Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNA
  22. Genetic cystic fibrosis transmembrane regulator 4016insT D1152H compound heterozygosity and male infertility: an Italian case report
  23. Reference intervals for serum cystatin C in healthy Mexican adults
  24. Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
  25. Quality control strategy to verify day-to-day imprecision of length of blood sedimentation reaction measurements with the TEST-1 analyzer
  26. Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up
  27. Proposal of a candidate international conventional reference measurement procedure for free thyroxine in serum
  28. Balkan Clinical Laboratory Federation − past, present and future trends
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.145/html
Scroll to top button